AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and ...

Check the time stamp on this data. Updated AI-Generated Signals for Abbvie Inc. (ABBV) available here: ABBV.

The maker of an augmented reality device that helps surgeons navigate spinal surgery says it's brought in a 20-year medical ...

Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other ...

One difference is the continued improvement of the parentage of North Chicago Community High School students on track to ...